

## Res. Asst. GÜLDEN PAÇACI ÇETİN

### Personal Information

Office Phone: [+90 352 207 6666](tel:+903522076666) Extension: 21186

Email: [guldenpacacietin@erciyes.edu.tr](mailto:guldenpacacietin@erciyes.edu.tr)

Web: <https://avesis.erciyes.edu.tr/guldenpacacietin>

Address: [drguldenp@gmail.com](mailto:drguldenp@gmail.com)

### International Researcher IDs

ORCID: 0000-0002-2368-3401

### Biography

2003-2010 Ankara Üniversitesi Tıp Fakültesi

2010-2015 Ankara Üniversitesi Tıp Fakültesi İç Hastalıkları

### Education Information

Post Doctorate of Medicine, Erciyes University, Tıp Fakültesi, Dahili Tıp Bil., Turkey 2019 - Continues

### Research Areas

Health Sciences

### Academic Titles / Tasks

Research Assistant, Erciyes University, Tıp Fakültesi, Dahili Tıp Bil., 2019 - Continues

Research Assistant, Ankara University, Ankara Faculty Of Medicine, 2011 - 2015

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye**  
Demir M., TUNAKAN DALGIÇ C., METE GÖKMEN E. N., SAVAŞ R., EROĞLU S., Ozden G., Orcen C., PAÇACI ÇETİN G., ARSLAN B., Bilgir F., et al.  
MEDICINA-LITHUANIA, vol.60, no.3, 2024 (SCI-Expanded)
- II. Characteristics of asthma in an older adult population according to sex and control level: why are asthma symptoms in older women not well-controlled?**  
KARADOĞAN D., YILMAZEL UÇAR E., YAVUZ Y., BAÇÇIOĞLU A., Oeztuerk A. B., Bozkurt N., Kavas M., Karaoglanoglu S., Celik G., AYDIN Ö., et al.  
JOURNAL OF ASTHMA, vol.61, no.6, pp.539-549, 2024 (SCI-Expanded)
- III. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma**

PAÇACI ÇETİN G., ARSLAN B., YILMAZ İ.

JOURNAL OF ASTHMA, vol.61, no.1, pp.20-26, 2024 (SCI-Expanded)

- IV. **The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma**  
ARSLAN B., PAÇACI ÇETİN G., YILMAZ İ.  
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, vol.36, no.4, pp.189-209, 2023 (SCI-Expanded)
- V. **Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?**  
ARSLAN B., PAÇACI ÇETİN G., Turk M., GÜLMEZ İ., YILMAZ İ.  
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol.183, no.10, pp.1071-1077, 2022 (SCI-Expanded)
- VI. **Venom immunotherapy and difficulties encountered before and during immunotherapy: Double sensitization, systemic reactions, treatment with omalizumab, and high dose VIT**  
PAÇACI ÇETİN G., YILMAZ İ., Turk M., ARSLAN B., Bahcecioglu S. N.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.1223-1234, 2022 (SCI-Expanded)
- VII. **A case of hypersensitivity developing against trace element solution in total parenteral nutrition, proved by skin prick test**  
PAÇACI ÇETİN G., Turk M., Bahcecioglu S. N., YILMAZ İ.  
EUROPEAN JOURNAL OF CLINICAL NUTRITION, vol.75, no.12, pp.1829-1831, 2021 (SCI-Expanded)
- VIII. **The Visible and Invisible Faces of the Iceberg of Type 2 Asthma**  
YILMAZ İ., PAÇACI ÇETİN G.  
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol.203, no.11, pp.1443-1444, 2021 (SCI-Expanded)
- IX. **Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma**  
YILMAZ İ., Nazik Bahcecioglu S., Turk M., TUTAR N., PAÇACI ÇETİN G., ARSLAN B.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.4, pp.1953-1959, 2021 (SCI-Expanded)

## Articles Published in Other Journals

- I. **The definition of remission in asthma should be unique and specific**  
Yılmaz I., ÇETİN g., Türk M.  
Tüberküloz ve Toraks, vol.72, no.2, pp.176-178, 2024 (ESCI)
- II. **Capsaicin Pretreatment Increases Mast Cell-Mediated But Not Histamine-Induced Wheal and Erythema Responses: A Proof-of-Concept Study**  
TÜRK M., YILMAZ İ., NAZİK BAHÇECİOĞLU S., PAÇACI ÇETİN G., Elieh-ali-komi D., Maurer M.  
ASTHMA ALLERGY IMMUNOLOGY, 2023 (ESCI)
- III. **Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma**  
YILMAZ İ., ÇETİN G. P., ARSLAN B., ŞEKER S., YILMAZ H. E. B., AKTAŞ E., köylüce s., ACAR E.  
Tüberküloz ve Toraks, vol.71, no.1, pp.75-93, 2023 (ESCI)
- IV. **Biologics for the treatment of severe asthma: Current status report 2023 Ağır astım tedavisinde biyolojikler: Güncel durum raporu 2023**  
PAÇACI ÇETİN G., Kepil Özdemir S., Can Bostan Ö., Öztop N., Çelebi Sözen Z., KARAKAYA G., Gelincik Akkor A., YILMAZ İ., MUNGAN V. D., BAVBEK S.  
Tüberküloz ve Toraks, vol.71, no.2, pp.176-187, 2023 (ESCI)
- V. **Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study**  
NAZİK BAHÇECİOĞLU S., TURK M., ATAYIK E., PAÇACI ÇETİN G., ARSLAN B., GÜLMEZ İ., YILMAZ İ.  
ASTIM ALLERJİ IMMUNOLOJİ, vol.20, no.2, pp.81-86, 2022 (ESCI)
- VI. **Safety Profiles of Biological Therapies Used in Asthma Treatment**

- PAÇACI ÇETİN G., ARSLAN B., YILMAZ İ.  
ASTIM ALLERJİ IMMUNOLOJİ, vol.20, no.3, pp.127-141, 2022 (ESCI)
- VII. **The adequacy of current diagnostic criteria for making a diagnosis of ABPA**  
Bahcecioglu S. N., Turk M., PAÇACI ÇETİN G., YILMAZ İ.  
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.70, no.2, pp.141-148, 2022 (ESCI)
- VIII. **The Management of Acute and Chronic Urticaria**  
YILMAZ İ., PAÇACI ÇETİN G., ARSLAN B., Turk M.  
ASTIM ALLERJİ IMMUNOLOJİ, vol.20, no.3, pp.202-204, 2022 (ESCI)
- IX. **Blood hyperreosinophilia: A diagnostic challenge**  
PAÇACI ÇETİN G., KÖSE M., ARSLAN B., YILMAZ İ.  
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.3, pp.408-415, 2021 (ESCI)
- X. **Long-term macrolide therapy in asthma**  
PAÇACI ÇETİN G., Arslan B., YILMAZ İ.  
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.4, pp.520-534, 2021 (ESCI)
- XI. **Asthma phenotype and endotype definitions**  
YILMAZ İ., PAÇACI ÇETİN G.  
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.2, pp.288-290, 2021 (ESCI)
- XII. **Should There be a Washout Period When Switching to Another Biological in Asthma?**  
PAÇACI ÇETİN G., Yilmaz H. E. B., YILMAZ İ.  
ASTIM ALLERJİ IMMUNOLOJİ, vol.17, no.1, pp.25-27, 2019 (ESCI)

## Metrics

Publication: 25

Citation (WoS): 23

Citation (Scopus): 27

H-Index (WoS): 2

H-Index (Scopus): 2